Trial Profile

A Phase I Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of a Human Monoclonal Antibody, CAP256V2LS (VRC-HIVMAB0102-00-AB) administered intravenously to HIV-negative and HIV-positive women or subcutaneously alone and in combination with VRC07- 523LS and /or PGT121 to HIV-negative women in South Africa

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CAP 256V2LS (Primary) ; CAP 256V2LS (Primary) ; TMB-380 (Primary) ; PGT 121
Indications HIV infections
Focus Adverse reactions; Therapeutic Use
Acronyms CAPRISA 012B

10 Apr 2023 New trial record
22 Feb 2023 Results(n-=42) assessing safety of Cap256v2ls and Vrc07-523Ls Antibodies Among Women in South Africa presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com